Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Nice catch, I glossed over it, sorry for my thinking you were way off base. Guess I still don't see it as being worth much of substance. just not sure what preparation could mean with so little money available. But hope may slant is way off.
"B-OM will make the most money after the phase 3 trial, which is in preparation."
Sure about that? Or just a wish shared by many (me too)? I'd love to see a site, but figure it is just your Easter wish for the spirit of rejuvenation of our lowly pps. Happy, happy.
From The Gastroenterology Advisor. More reasons why effective treatments for Covid are necessary
https://www.gastroenterologyadvisor.com/inflammatory-bowel-diseases-ibd/assessment-of-ibd-medications-on-covid-19-outcomes/?utm_source=newsletter&utm_medium=email&utm_campaign=gas-update-hay-20210402&cpn&hmSubId=QMqxYuklsMg1&hmEmail=LQnywRXkwFIUv5pNToHwxDh3l-C0VOAd0&NID=-1&email_hash=ada783b62c848f3430da90d1edaebea5&mpweb=1323-129483-6680291
If thousands have died when hundreds of millions have been spared the potentials ravages of coivd, it is a fair trade off. Of course, if, and that is the question, B worked to fend off Covid, even better. If hundreds of millions took B for Covid, there would likely be deaths from some adverse reactions, probably from blood pressure related issues.
Steelyeye, I read the disclosures too, and am glad to see that they are honestly included. The Pharma research industry is interbred as are most research areas. No biggie, just how it is. Why not look at the article itself? I hate the fact that so much is rigged, but it all isn't.
Will do, soon I will have a MinneM book shelf.
Further progress on UC
March 31, 2021
Induction Therapy for Ulcerative Colitis with ABX464 is Safe and Well Tolerated
Virginia A. Schad, PharmD, RPh
Ulcerative colitis
The researchers observed high maintenance of remission rates, with up to 71% of patients in remission on ABX464 at week 8 and experiencing sustained clinical remission until week 52.
Further clinical development of ABX464 (Abivax, Paris, France), as a novel, first-in-class, orally administered small molecule for the treatment of ulcerative colitis (UC) is justified, based on a randomized study published in Gastroenterology.
Preclinically, ABX464 demonstrated a reduction in dextran sulfate sodium-induced colitis in mice and produced long-term protection while also decreasing miR-124 levels after stopping treatment. Researchers conducted a phase 2a to evaluate the safety and efficacy of ABX464 in patients with moderate to severe UC that involved an 8-week placebo-controlled, double-blind induction phase (ClinicalTrials.gov Identifier NCT03093259) (ABX464, n=20; placebo, n=9) followed by an open-label long-term extension phase (ClinicalTrials.gov Identifier NCT03368118) (prior ABX464, n=11; prior placebo, n=5).
The researchers found that 78.3% of patients receiving ABX464 experienced adverse events (AEs) compared with 55.6% receiving placebo. The most common AEs in the ABX464 group were abdominal pain and headache (17.4% each). The researchers also found that the difference in endoscopic improvement after 8 weeks of treatment was statistically significant. Mean change from baseline in the Mayo Clinic Score (MCS) and the partial Mayo Clinic Score (pMCS) at week 8 were substantially greater in ABX464 patients compared with placebo.
The researchers observed high maintenance of remission rates, with up to 71% of patients in remission on ABX464 at week 8 and experiencing sustained clinical remission until week 52. Of the patients who entered the long-term extension phase without clinical remission, 58.3% achieved this end point after 1 year. Additionally, patients receiving a total of 60 weeks of ABX464 had median fecal calprotectin levels of 20.8 µg/g.
Today’s Top Picks for You on Gastroenterology Advisor
Association Found Between Liver Fibrosis and HFpEF, Research Needed to Identify Causal Interactions
Endoscopic Submucosal Dissection for GI Lesions Is Safe and Associated With Low Recurrence Rate
Intravenous Immunoglobulin Efficacious in Treating Moderate COVID-19 Pneumonia
CONTINUE READING
“In conclusion, induction therapy with ABX464 50 mg QD appeared safe and well tolerated,” stated the authors. They added, “After 8 weeks of treatment, ABX464 appeared more effective than placebo in achieving endoscopic improvement and reduction of MCS and pMCS.”
Disclosure: Several study authors declared affiliations with the pharmaceutical industry. Please see the original reference for a full list of authors’ disclosures.
Reference
Vermeire S, Hébuterne X, Tilg H, De Hertogh G, Gineste P, Steens JM; On behalf of the ABX464 Investigators. Induction and long-term follow-up with ABX464 for moderate-to-severe ulcerative colitis: results of phase 2a trial. Gastroenterol. Published online February 24, 2021. doi: 10.1053/j.gastro.2021.02.054
"Anti-mask, anti-vax and pro-freedom"
If you have kids or grandkids, do you want them to go unvaccinated against common, sometimes deadly childhood diseases, to go along with your ideal of freedom. Virtually all school boards address that issue and require vaccinations, why is covid different? I can see no rational reasons, just ideological ones. The freedom to get yourself and others sick is not freedom, it is selfishness.
"No, you’re safe, but take precautions in case you aren’t."
Realty is complicated, as we see. Like investing in little bios.
"The realization sinks in: no great data or the trial would have been stopped early"
Stopping a Ph 2b because of great data is not a usual occurrence. I know I might have heard of it, but can't recall when. Stopping after the 2b concludes, if there is really great data, may be more common, though it is still very rare.
This article (below) in KOS, comes as close to answering the question as I could find, but still does not specifically address the question of terminating a 2b because of great data. I found nothing in the regs of the literature that even approached that.
https://www.dailykos.com/stories/2020/9/2/1974436/-How-bad-would-it-be-if-the-FDA-rushed-the-release-of-a-vaccine-Let-s-check-in-with-the-FDA
There are two ongoing tests of Brilacidin, one for covid and one related to Irritable Bowel conditions being conducted in N. Italy by Alfa Sigma, a mid sized company that specializes in IBD issues. We'll all know soon enough if IPIX has success with these and money for pursuing other B uses, and even Kevetrin. As always, high leverage, high risk, but as a really long term holder you already knew that.
"i didn't say that I thought that the CEO never read the board:
"I'm told the CEO doesn't read this board" doesn't sound the same, does it?"
Sounds pretty close to me, unless you reason(s) not to trust what you heard to be accurate.
I agree, it wouldn't hurt for him to drop in here once in a while. I still think a shareholder meeting every year or two (three?) would be nice. Flights are still cheap and so are rooms, though covid remains a concern for the present.
Nice post LR, though what you and others have heard about Leo not ever looking at the MB is a view I don't share. I don't think Leo spends his time obsessing on the mb, that's almost a full time occupation as too many of us have learned. But I do think that he looks at it occasionally, I know I would. Why not? If he answers some mail, it does not seem irrational to believe he peeks at the mb occasionally. He might have his perspectives enhanced. A little bio with 8 or 9 solid shots on goal sitting at less than 3 dimes has not always benefitted by acutely effective decision-making, imo. Ok, we have very little debt, and a hand full of millions ahead, and are not at risk of going out of business in the near future, as many little bios often are. All in all we are ok, imo.
He also said what any sensible person already knew to be true...”it’s total insanity to be wearing masks outdoors.”
C'mon Dane, if people are tightly packed out doors, of course mask are wise. Is it such an imposition to make yourself and others a bit safer?
Steve, the vitamin stuff seems reasonable and useful (I overdoes on D3 myself), but the sites over to the right seem like a party for nutcakes. Anti-vaccine, etc.
Grew some hair back, it stuck around for a while, then sayonara. Interesting, I made $8,000. However, I had a lots of calls, and they were worth upwards of $250,000 at one point. I lost most of their value when a front page article was written in regarding a local judge (who had no authority in the matter, though this was not stated in the article, as I recall) made a negative finding on the company (forget what it was, exactly) and my options were quickly under water. I sold on an up tick and made the 8k. Then a week later, they marched back to where they were on the last day at peak, before the article. Lots of us little guys got sheared. Not sure what the lesson I learned was, but SEC never raised a little finger, as I recall. Maybe it was all above board, and maybe not.
"Indeed. But patients on placebo will get better, not just those on placebo."
I'm not so sure spotts. Some on the placebo may not get better, and may end up on vents, and some may even die. After all, if they are in the hospital at all, they are in relatively bad shape in the first place. Though as treatments get more sophisticated, I agree that most on the placebo (SOC) will get better. Which is why I agree with TIAB and others to the extent that B might get a better showing if our patient group were patients with milder symptoms.
Ok, I'm killing a dead horse, but I don't think that monoclonal anti-bodies, which have been very effective with the original strain of covid at least, have even been included in SOC (and I am not sure if they were in the IPIX study). the federal site just mentions SOC, but did not define it.
Wow, Billy, thoughtful and extensive discussion.
Despite the fact that most docs and nurses involved don't know who got B and who did not, they can usually see who is getting better and who is not. As I posted, once when I was in a hair study, it was really clear that a lot of baldies were growing at least some hair. Some involved were buying the company's stock (including me). Why would the case of IPIX be different, though I am not aware of what restrictions there are on stock purchases. There were none of which I was aware, when I was in the study, but that was decades ago.
Kelt, I'm not sure if I buy the "altering dna" theory, I but don't know enough to categorically say it is false (or true). Either way, we know BP will be altering the monoclonal antibody treatments, for good or ill. We can all hope that Fauci's call for effective covid treatments includes B.
"Some good discoveries lately ... ??... Go IPiX"
? Vlady 1, my interest is perked up, what are your referring to?
White Bronco, you and Bizzy and Pete raise good points. Kind of makes my head spin. The need for anti-virals remains, and that train will keep on track, let's hope B is among the proven leaders. My hunch, as I am typing, is that newly revised monoclonal anti-bodies will also be joining the frey.
While watching late night tv I ran across some numbers we've all been exposed to at one time or another, but which seem to have been strangely, overlooked regarding their potential impact. Monoclonal anti- bodies, administered in one hour infusions, have been found in various studies to be between 70% and as high as 100% effective at keeping covid-19 positive individuals alive and out of hospitals. None the less, these extremely effective and often studied treatments are not universally being used, though they are widely available. A $150,000,000 appropriation in Biden's $1.9 trillion Bill will make them free and widely used. This is great news at one level. But at another, it means that, along with a steady drip of newer covid treatments, the relative value of B for C, even if proved highly effective, will lose some of its luster and value. I'm not saying this to present a negative slant, highly effective results will still be a medical boon and an economic success for IPIX, just less of one than most of us (or at least me) have been expecting. Just sayin'.
Probably much more than that, as medical miscues are one of the leading causes of death in the US (3rd leading cause) and accountable for 250,000 deaths a year.
https://www.statnews.com/2016/05/03/medical-errors-death/#:~:text=Medical%20errors%20are%20thir
Nice catch, TheWayISeeit. I am not sure what to make of this? The findings look huge. If B for C were this effective I'm thinking we'd be flirting with a $10 or more (but who knows) pps. Kintor is a $5 Billion dollar Chinese company, the real deal. I'm surprised this is not stirring up more interest here, am I missing something? The Kintor pps is about $3, if it were $10 it would be a $17 Billion dollar company, but rests at $5 Billion or so, for the present. Are we here expecting too much if we see a very successful B for C? And, like IPIX there are other potential products in the mix (cancer). I don't know.
Jeez, 3dtdman, you humbly claim to be no expert, but can I say you know lots of stuff? I know enough to know that. This is the kind of stuff that peripherally touches IPIX products, especially B for C, so its good to get educated. Much appreciate that.
"I got fired up about this technology, wrote a paper,"
Wow, 3dtdman, you really got to be an expert, that's always a good start. Interesting, I used to do White Papers on disaster/public health/medical issues and sent them to my Congressman, Senators, etc. Nada. Sometimes form letters, sometimes not. Nada. It kind of makes my old saw of "Write, email, etc." to the politicisms sound naïve, though the letters are counted, if nothing else. I still do papers and put them on some of the sites, but mainly for fun, little if anything comes of it, but I feel better.
Why not post it here (Your paper, you don't need your name on it), lots of smart folks (and of course some nut cakes, too) but all in all -----
I'm sending the Sterilay stuff to one of the board members in our condo, we have UVC/HEPA filters in the elevators and near the front desk, but still have all ten corridors uncovered. Good steer, much appreciated.
3dtman, now that we have made the board experts re UV and UVC variants, is there any way we can make some money on this? Lame joke, but it does bring to mind the Israel materials just posted. I think it is an attempt to get a stock price boost from a product that may or may not be really worth much. After all, vinegar, diluted bleach and lots of other products ingested by nose (Uhhgg) will kill many if not all bacterial and viral agents.
B ingested by nose looks potentially effective in killing viruses and bacteria too, but how would a person go about ingesting it everywhere they went to keep a viable dose in the nose, Just seems kind of nuts, but on the surface it may be the thing stock flippers jump at, at the first publication. Wish I could recall the last Israeli company that did something like this. They've got their scammers, too. Unless this is all legit, who knows?
Try this: From the bottom of the federal document below
"UVC radiation can cause severe burns (of the skin) and eye injuries (photokeratitis). Avoid direct skin exposure to UVC radiation and never look directly into a UVC light source, even briefly. If customers identify a problem with a UVC lamp, they can report it to the manufacturer and the FDA."
Here is the complete FDA document with probably more than we need to know about UVC.
https://www.fda.gov/medical-devices/coronavirus-covid-19-and-medical-devices/uv-lights-and-lamps-ultraviolet-c-radiation-disinfection-and-coronavirus#:~:text=Direct%20exposure%20of%20skin%20and%20eyes%20to%20UVC,directly%20at%20a%20UVC%20lamp%20source%2C%20even%20briefly.
Interesting, now I can't open the site I posted. Let me go back tp see what's what. The essence was that UVC can really hurt eyes and skin, but I know that statement needs some proof.
Second response. Yes, it does (pose a risk to skin and eyes).
https://wwwhttps//www.klaran.com/klaran-university/about-uvc.fda.gov/medical-devices/coronavirus-covid-19-and-medical-devices/uv-lights-and-lamps-ultraviolet-c-radiation-disinfection-and-coronavirus
Ok,. we paly links. Here is the first:
https://www.klaran.com/klaran-university/about-uvc
UVC light is very effective in killing ANY living things: virus, bacteria, mold, mildew, etc. But when used as a COVID killer (really, mostly in the air), for example, it is best used in accord with good HEPA filters and perhaps negative ions. This is so because UVC does not kill instantly, but takes a second or two or even lots more, depending on the environmental conditions. And it can really hurt a person's eyes, so the bulbs, which need to be very powerful, need to be completely shielded. In short UVC is not a real answer to airborne COPVID. Just another useful tool in certain circumstances. (We have some UVC/HEPA filter/negative ion air cleaners in our condo, and you have to change/clean the HEPA filters, clean off and eventually replace the bulbs, etc. to keep it all working. Kind of a pain, but it provides SOME help re COVID, flu and whatever nastiness is in our condo air. FWIW) Final thought, UVC has been used for decades commercially and in hospitals to clean the air, and sometimes is left on in sealed rooms overnight to sterilize environmental surfaces. But enough about UVC.
Cabel, really interesting stuff, where are you finding it?
Sure will Farrell, in fact my brother and wife lived in Carol Stream and left two decades or so ago.
If there is any way to find out, I will. I wonder how to go about it. Ok, after spending decades around hospitals, public health folks and all, I should be able to come with something. On the other hand, please don't think ill of me if I fail miserably (Always a good chance of that).
Wow, I did not know that Northwestern (a class act) was a B for C site. We live near, our extended families use Northwestern facilities and docs and will see what we can see or hear.
Well, I guess I'd rather have the tests in Toledo too. Actually, I appreciate your idealistic position, but regardless, it is Leo's call, and not a bad one if viewed as just a dollars and cents/competence issue.
I thought it was clear that I was referring to what Putin might say if the testing works out. If it was not, I hope it is now.
I thought it was clear that I was referring to what Putin might say if the testing works out. If it was not, I hope it is now.